Cargando…

Monthly Patient Volumes of Buprenorphine-Waivered Clinicians in the US

This cross-sectional study examines the number of patients prescribed buprenorphine by US clinicians who were waivered to treat 30, 100, or 275 patients concurrently.

Detalles Bibliográficos
Autores principales:	Duncan, Alexandra, Anderman, Jared, Deseran, Travis, Reynolds, Ian, Stein, Bradley D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445589/ https://www.ncbi.nlm.nih.gov/pubmed/32833015 http://dx.doi.org/10.1001/jamanetworkopen.2020.14045

Ejemplares similares

Analysis of US County Characteristics and Clinicians With Waivers to Prescribe Buprenorphine After Changes in Federal Education Requirements
por: Nguyen, Thuy, et al.
Publicado: (2022)

Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
por: Spetz, Joanne, et al.
Publicado: (2022)

Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver
por: Lanham, Holly J., et al.
Publicado: (2022)

Buprenorphine Waiver Attitudes Among Primary Care Providers
por: Lai, Benjamin, et al.
Publicado: (2022)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
por: Jones, Christopher M., et al.
Publicado: (2023)

State alignment with federal regulations in 2022 to relax buprenorphine 30-patient waiver requirements
por: Silwal, Anita, et al.
Publicado: (2023)

Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes
por: Hirchak, Katherine A., et al.
Publicado: (2022)

US Support for a WTO Waiver of COVID-19 Intellectual Property
por: Contreras, Jorge L.
Publicado: (2021)

Clinical trials waiver in India-some considerations
por: Juneja, Atul, et al.
Publicado: (2018)

Changes in Buprenorphine and Methadone Supplies in the US During the COVID-19 Pandemic
por: Chen, Annie Y., et al.
Publicado: (2022)

Association of Indiana’s Section 1115 Waiver With Medicaid Enrollment
por: Stimpson, Jim P., et al.
Publicado: (2019)

Trends in the Use of Buprenorphine in US Emergency Departments, 2002-2017
por: Rhee, Taeho Greg, et al.
Publicado: (2020)

Expiration of State Licensure Waivers and Out-of-State Telemedicine Relationships
por: Bressman, Eric, et al.
Publicado: (2023)

Pharmacy Availability of Buprenorphine for Opioid Use Disorder Treatment in the US
por: Weiner, Scott G., et al.
Publicado: (2023)

Training Clinicians to Support Aging in Place in a Medicaid Home and Community-Based Waiver Program
por: Spoelstra, Sandra, et al.
Publicado: (2020)

Initial Findings From an Acute Hospital Care at Home Waiver Initiative
por: Adams, Danielle, et al.
Publicado: (2023)

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021
por: Thakrar, Ashish P., et al.
Publicado: (2021)

The impact of article processing charge waiver on conducting research in low-income countries
por: Abdul Baki, M-Nasan, et al.
Publicado: (2021)

Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021
por: Nguyen, Thuy D., et al.
Publicado: (2022)

Get waivered remote: Nationwide, remote DEA-x waiver course in response to COVID-19
por: Martin, Alister, et al.
Publicado: (2021)

Evaluation of the Conrad 30 Waiver Program’s Success in Attracting International Medical Graduates to Underserved Areas
por: Ramesh, Tarun, et al.
Publicado: (2023)

A Descriptive Study on Opioid Misuse Prevalence and Office-Based Buprenorphine Access in Ohio Prior to the Removal of the Drug Addiction Treatment Act of 2000 Waiver
por: McKnight, Erin R, et al.
Publicado: (2023)

Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment
por: Stein, Bradley D., et al.
Publicado: (2023)

Trends in Buprenorphine Prescribing for Opioid Use Disorder by Psychiatrists in the US From 2003 to 2021
por: Creedon, Timothy B., et al.
Publicado: (2023)

Extended-release monthly buprenorphine injection
por: Cuperfain, Ari B., et al.
Publicado: (2023)

Home and Community-Based Services Waivers
por: Duckett, Mary Jean, et al.
Publicado: (2000)

Barriers and Facilitators to Clinician Readiness to Provide Emergency Department–Initiated Buprenorphine
por: Hawk, Kathryn F., et al.
Publicado: (2020)

Transparency and Accountability of Medicaid Section 1115 Waiver Demonstration Programs Under the Affordable Care Act
por: Lopez, Leo, et al.
Publicado: (2020)

Time to boost COVID-19 vaccine manufacturing: The need for intellectual property waiver by big pharma
por: Okereke, M., et al.
Publicado: (2021)

Association Between Medicaid Waivers and Medicaid Disenrollment Among Autistic Adolescents During the Transition to Adulthood
por: Carey, Meghan E., et al.
Publicado: (2023)

The Effects of Methadone and Buprenorphine on Testis of Rats
por: Corsi, Karen F.
Publicado: (2012)

Attending a Biopsychosocially Focused Buprenorphine Training Improves Clinician Attitudes
por: Russell, Holly Ann, et al.
Publicado: (2021)

Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic
por: Alinsky, Rachel H., et al.
Publicado: (2022)

State Health Reform and the Role of 1115 Waivers
por: Riley, Trish
Publicado: (1995)

Impact of the Maine Medicaid waiver for the mentally retarded
por: Coburn, Andrew F., et al.
Publicado: (1990)

Vaccination Perceptions of College Students: With and without Vaccination Waiver
por: Jadhav, Emmanuel D., et al.
Publicado: (2018)

29. Use of Buprenorphine for Opioid Use Disorder among US Adolescents and Young Adults During the COVID-19 Pandemic
por: Alinsky, Rachel, et al.
Publicado: (2022)

Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic
por: Jones, Christopher M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t417td397ua2fkt5gg76865sre